The ability of the various PLC isoforms to alter the signaling of major oncogenic pathways implicated in cancer like the PI3K/Akt/mTOR, RAS/RAF/MAPK/ERK, and JAK/STAT pathways underscore why it is important that future studies focus on understanding the therapeutic potential of PLCs in cancer. This evidence concerns the gene HSPG2 and cancer.